Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: More Bumps On The Abuse-Deterrent Opioid Road

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

You may also be interested in...



Newly Hatched Mirum To Focus On Rare Liver Disease Candidates Shelved By Shire

With $120m in Series A funding, the new company headed by former Lumena execs will advance maralixibat into Phase III in Alagille syndrome and progressive familial intrahepatic cholestasis. Shire acquired Lumena for $260m in 2014, but lost interest in the drug.

Keeping Track: US FDA Approves Emflaza And Parsabiv, Turns Down Opioid/Anti-Emetic Combo CL-108

The latest drug development news and highlights from our FDA Performance Tracker.

Keeping Track: Novartis' Ribociclib, Tesaro's Niraparib Submitted; Catalyst Clears Path For Firdapse Resubmission

In retrospect, the European Society for Medical Oncology meeting was a showcase for pivotal trial data included in a burst of targeted therapy new drug applications, and more drug development news and highlights from our FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM013214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel